Pharmacological Research · 2024 · 11 citations · 28 references
Life SciencesMolecular BiologyPharmacologyCell SignalingDrug DiscoverySignal TransductionAngiogenesisEndothelial ActivationGrowth Factor SignalingReceptor Tyrosine Kinase SignalingApoptosis Of Endothelial CellsCell Growth RegulationEndothelial Tube FormationLigand CaptureOsteopontin FunctionVascular Endothelial Growth FactorVascular Endothelial Growth Factor ReceptorsVascular Endothelial Growth Factor Signaling
The osteopontin-derived peptide FOL-005 stimulates hair growth. Using ligand-receptor glyco-capture technology we identified neuropilin-1 (NRP-1), a known co-receptor for vascular endothelial growth factor (VEGF) receptors, as the most probable receptor for FOL-005 and the more stable analogue FOL-026. X-ray diffraction and microscale thermophoresis analysis revealed that FOL-026 shares binding site with VEGF in the NRP-1 b1-subdomain. Stimulation of human umbilical vein endothelial cells with FOL-026 resulted in phosphorylation of VEGFR-2, ERK1/2 and AKT, increased cell growth and migration, stimulation of endothelial tube formation and inhibition of apoptosis in vitro. FOL-026 also promoted angiogenesis in vivo as assessed by subcutaneous Matrigel plug and hind limb ischemia models. NRP-1 knock-down or treatment of NRP-1 antagonist EG00229 blocked the stimulatory effects of FOL-026 on endothelial cells. Exposure of human coronary artery smooth muscle cells to FOL-026 stimulated cell growth, migration, inhibited apoptosis, and induced VEGF gene expression and VEGFR-2/AKT phosphorylation by an NRP-1-dependent mechanism. RNA sequencing showed that FOL-026 activated pathways involved in tissue repair. These findings identify NRP-1 as the receptor for FOL-026 and show that its biological effects mimic that of growth factors binding to the VEGF receptor family. They also suggest that FOL-026 may have therapeutical potential in conditions that require vascular repair and/or enhanced angiogenesis.
28
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Aidin Rawshani, Araz Rawshani, Stefan Franzén et al. · New England Journal of Medicine · 2017 · 1.4K citations · Full text
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
Lasse Folkersen, Stefan Gustafsson, Qin Wang et al. · Nature Metabolism · 2020 · 772 citations · Full text